Cidara Therapeutics (NASDAQ:CDTX) Downgraded to "Buy" at StockNews.com
Cidara Therapeutics (NASDAQ:CDTX) Downgraded to "Buy" at StockNews.com
StockNews.com downgraded shares of Cidara Therapeutics (NASDAQ:CDTX – Get Rating) from a strong-buy rating to a buy rating in a research note issued to investors on Monday.
證券新聞下調股份 賽達拉治療 (納斯達克:CDTX — 獲得評分) 從周一發給投資者的研究報告中的強買入評級到買入評級。
Cidara Therapeutics Stock Performance
賽達拉治療股票表現
CDTX opened at $0.93 on Monday. The firm's 50-day simple moving average is $0.74 and its 200-day simple moving average is $0.69. The firm has a market cap of $66.47 million, a price-to-earnings ratio of -1.69 and a beta of 1.31. Cidara Therapeutics has a twelve month low of $0.40 and a twelve month high of $1.60.
周一 CDTX 的開盤價為 0.93 美元。該公司的 50 天簡單移動平均線為 0.74 美元，而 200 天的簡單移動平均線為 0.69 美元。該公司的市值為 66.47 萬美元，價格與盈利比率為 -1.69，測試版為 1.31。西達拉治療有十二個月低點 0.40 美元和十二個月高點 1.60 美元。
Cidara Therapeutics (NASDAQ:CDTX – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.30 by ($0.13). Cidara Therapeutics had a negative net margin of 54.21% and a negative return on equity of 480.89%. The firm had revenue of $40.74 million during the quarter, compared to analyst estimates of $37.50 million. As a group, sell-side analysts anticipate that Cidara Therapeutics will post -0.29 EPS for the current fiscal year.
賽達拉治療學 (NASDAQ: CDTX-獲取評級) 最後公佈其季度收益業績週四, 11 月 3 日.該生物技術公司報告了本季度每股盈利 0.17 美元，缺少分析師的共識估計為 0.30 美元（0.13 美元）。西達拉治療的負淨利潤率為 54.21％，負資產回報率為 480.89%。該公司在本季度的收入為 4.74 億美元，而分析師估計為 37.50 萬美元。作為一個集團，賣方分析師預計 Cidara 治療將在當前財政年度發布 -0.29 每股盈利。
Institutional Trading of Cidara Therapeutics
賽達拉治療的機構交易
Cidara Therapeutics Company Profile
西達拉治療公司簡介
(Get Rating)
(取得評分)
Cidara Therapeutics, Inc is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
Cidara Therapytics 公司是一家生物技術公司，從事新型抗感染藥的發現，開發和商業化。其產品管道包括雷薩富金和雲休克。該公司由凱文·福雷斯特，凱文·朱迪斯和 H. 肖沃倫於 2012 年 12 月成立，總部設在加利福尼亞州聖地亞哥。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Cidara Therapeutics (CDTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
- 獲取有關西達拉治療學（CDTX）的研究報告的免費副本
- 諾斯羅普·格魯曼拋售是一個機會嗎？
- 新的首席執行官在裝甲股票下最糟糕的背後是什麼？
- 微軟對聊天 GBT 的投資對 MSFT 股票意味著什麼？
- 分析師喜歡適合斯凱奇美國
- 我們可以相信標普 500 的反彈
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 CIDARA 治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Cidara 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。